AKN Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product

Akorn, Inc. (AMEX:AKN) today reported net sales of $14.5 million for the third quarter 2006, an increase of 32% vs. third quarter 2005 net sales of $11.0 million. Gross profit of $6.0 million or 41% of third quarter 2006 net sales, represents an increase of 62% vs. gross profit of $3.7 million or 33% of net sales for the third quarter 2005. Net loss available to common stockholders for the third quarter 2006 was $(1.2) million, or $(0.02) per diluted share vs. a $(3.6) million net loss available to common stockholders for the third quarter 2005, or $(0.14) per diluted share. During the third quarter of 2006, net loss available to common stockholders was adversely impacted by stock option expense of $0.3 million as compared to zero in the third quarter of 2005, and product development milestone expenses of $371,000 for the Akten (AK-1015) clinical trial and the Sofgen Pharmaceuticals development and supply agreement. For the nine months ended September 30, 2006 as compared to the nine months ended September 30, 2005, net sales were $56.7 million vs. $33.7 million, an increase of 68%. Gross profit was $22.6 million or 40% of net sales, vs. $11.9 million or 35% of net sales. Net loss available to common shareholders was $(0.6) million vs. a net loss of $(8.0) million. For the first nine months of 2006, net income was adversely impacted by stock option expense of $1.0 million as compared to zero in the first nine months of 2005, product development milestone expenses of $613,000, and one-time non-recurring interest expense of $1.1 million recorded upon the early retirement of convertible debt. Highlights for the Third Quarter 2006 include: One new business development agreement was signed, with Sofgen Pharmaceuticals, which adds one new generic drug to Akorn's product development pipeline. Combined with Fidia, Natco (2), and Cipla, this brings our total to five new business development agreements signed in 2006. Two new contract manufacturing supply agreements were signed, one with GeneraMedix, Inc. and one with Advanced Vision Research, Inc. As previously announced, we believe that these two supply agreements will increase Contract Manufacturing sales by approximately 50% on an annualized basis beginning in 2007. Both supply agreements are expected to contribute revenue in the fourth quarter of 2006. Two product approvals were received from the FDA: Bal-in-Oil injection and BSS Ophthalmic Solution, and three products were launched: Bal-in-Oil, Sufenta, and Sublimaze. To date, Akorn has received 10 ANDA product approvals in 2006. Clinical trials began for Akten (AK-1015), Akorn�s internally developed new drug indicated for use in ocular anesthesia. Of the 200 patients that are necessary to complete the clinical trial, 104 patients have been enrolled. We expect to file the 505(b)(2) NDA in the first half of 2007. Eight ANDA�s were submitted to the FDA. For the year, Akorn has submitted 19 ANDA�s and has a total of 27 ANDA�s under review with the FDA. A $3.5 million purchase order for the procurement of Ca-DTPA and Zn-DTPA was received from the Department of Health and Human Services (HHS). This was the first purchase order that accessed the one million unit purchase option provided for in our 2005 contract award with HHS. Akorn expects to ship this order in the fourth quarter of 2006. A $3.56 million equity investment was received from the Serum Institute of India, Ltd, one of Akorn�s long term strategic partners. Akorn expects to use these proceeds to begin the development of its biologics product pipeline. Arthur S. Przybyl, President and Chief Executive Officer stated, "Our third quarter results continue to reflect our commitment to achieve our 2006 stated objectives: 50% year-over-year revenue increase, 40% gross margin, positive net income, 20 ANDA regulatory filings, 10 product approvals, and the completion of our lyophilization validation efforts. �Late last week, our new liquid fill injectable/lyophilization product fill line was granted clearance by the FDA to manufacture and commercialize liquid injectable products. This action will allow us to further upgrade and automate our Decatur manufacturing facility. We expect to complete validation efforts on our lyophilizers prior to year end. Commercialization of the new lyophilizers will require a successful prior approval inspection (PAI) to be conducted by the FDA. Also in the third quarter, we retired our operating lease and purchased our two lyophilizers for $1.5 million, resulting in cash savings of approximately $613,000. �We continue to develop four important products for anticipated product launches in 2008. Two proprietary products are being developed internally. AK-1015, now named Akten, is indicated for ocular anesthesia, continues to undergo clinical trials, and we expect to file our 505(b)(2) NDA in the first half of 2007. Formulation work continues on Minolok, our licensed patent from the University of Texas M.D. Anderson Cancer Center, and we expect to file a 510(k) in the first half of 2007. Two undisclosed generic products are being developed externally through Cipla and Sofgen, respectively, and we remain confident and on track for anticipated product launches in 2008. For these two products, the recent FDA announcement that specific generic drugs could be eligible for priority review is an additional benefit, potentially reducing the regulatory approval time for these two products. Akorn applauds this effort by the FDA to continue to help lower U.S. healthcare costs. �Finally, although not immediately apparent, Serum Institute of India�s equity investment in Akorn is expected to be the beginning of a long term strategic partnership to expand our portfolio of products to eventually include biologics and vaccines.� Conference Call Akorn will host a conference call on Monday October 30, 2006, beginning at 5:00 p.m. Eastern Time to discuss third quarter 2006 operating results. The dial-in numbers are (800) 289-0508 for domestic callers and (913) 981-5550 for international callers. Alternatively, analysts, investors and other interested parties are invited to participate by visiting the Company's website, www.akorn.com, and clicking on the live webcast icon located on the home page, or http://www.videonewswire.com/event.asp?id=35878. Please plan to log on at least ten minutes prior to the designated start time so management may begin promptly. About Akorn, Inc. Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company's website at www.akorn.com. Materials in this press release may contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements give our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual results may vary materially, and there are not guarantees about the performance of our stock. Any forward-looking statements represent our expectations or forecasts only as of the date they were made and should not be relied upon as representing our expectations or forecasts as of any subsequent date. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise, even if our expectations or forecasts change. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Other factors besides those listed there could also adversely affect our results. � AKORN, INC. CONDENSED CONSOLIDATED BALANCE SHEETS IN THOUSANDS � SEPTEMBER 30, DECEMBER 31, � 2006� � 2005� � (UNAUDITED) � (AUDITED) ASSETS CURRENT ASSETS Cash and cash equivalents $ 19,523� $ 791� Trade accounts receivable (less allowance for doubtful accounts of $1 and $13, respectively) 6,939� 3,222� Inventories 10,421� 10,279� Prepaid expenses and other current assets � 1,206� � 1,402� TOTAL CURRENT ASSETS 38,089� 15,694� PROPERTY, PLANT AND EQUIPMENT, NET 33,244� 31,071� OTHER LONG-TERM ASSETS Intangibles, net 9,164� 10,210� Other � 98� � 120� TOTAL OTHER LONG-TERM ASSETS � 9,262� � 10,330� TOTAL ASSETS $ 80,595� $ 57,095� LIABILITIES AND SHAREHOLDERS� EQUITY CURRENT LIABILITIES Current installments of debt $ 387� $ 7,044� Trade accounts payable 2,039� 3,046� Accrued compensation 1,674� 1,519� Customer accrued liabilities 538� 135� Accrued interest payable -� 2,514� Accrued expenses and other liabilities � 1,126� � 1,202� TOTAL CURRENT LIABILITIES 5,764� 15,460� LONG-TERM LIABILITIES Long-term debt, less current installments 309� 602� Product warranty � 1,131� � -� TOTAL LONG-TERM LIABILITIES � 1,440� � 602� TOTAL LIABILITIES � 7,204� � 16,062� SHAREHOLDERS� EQUITY Common stock, no par value � 150,000,000 shares authorized; 81,000,130 and 27,618,745 shares issued and outstanding at September 30, 2006 and December 31, 2005, respectively � 136,863� 67,339� Series A Preferred Stock, $1.00 par value, 257,172 shares authorized and issued, 241,122 shares outstanding at December 31, 2005 -� 27,232� Series B Preferred Stock, $1.00 par value, 170,000 shares authorized, 141,000 shares issued, 74,195 outstanding at September 30, 2006 and 106,600 outstanding at December 31, 2005 � 7,854� 10,758� Warrants to acquire common stock 7,312� 13,696� Accumulated deficit � (78,638) � (77,992) TOTAL SHAREHOLDERS� EQUITY � 73,391� � 41,033� TOTAL LIABILITIES AND SHAREHOLDERS� EQUITY $ 80,595� $ 57,095� � AKORN, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS IN THOUSANDS, EXCEPT PER SHARE DATA (UNAUDITED) � THREE MONTHS ENDED NINE MONTHS ENDED � SEPTEMBER 30, � SEPTEMBER 30, � 2006� � 2005� � 2006� � 2005� Revenues $ 14,490� $ 10,985� $ 56,695� $ 33,744� Cost of sales � 8,539� � 7,317� � 34,056� � 21,881� GROSS PROFIT 5,951� 3,668� 22,639� 11,863� Selling, general and administrative expenses 4,226� 3,894� 13,379� 10,961� Amortization and write-down of intangibles 345� 353� 1,046� 1,157� Research and development expenses � 2,649� � 1,438� � 6,815� � 4,203� TOTAL OPERATING EXPENSES � 7,220� � 5,685� � 21,240� � 16,321� OPERATING INCOME (LOSS) (1,269) (2,017) 1,399� (4,458) Interest income/(expense) - net 230� (595) (855) (1,705) Debt Retirement Gain/(Expense) -� -� (391) 1,212� Other Expense � (28) � -� � (57) � -� INCOME/(LOSS) BEFORE INCOME TAXES (1,067) (2,612) 96� (4,951) Income tax provision � -� � 2� � -� � 17� NET INCOME/(LOSS) (1,067) (2,614) 96� (4,968) Preferred stock dividends and adjustments � (182) � (1,015) � (742) � (2,991) NET INCOME/(LOSS) AVAILABLE TO COMMON STOCKHOLDERS $ (1,249) $ (3,629) $ (646) $ (7,959) NET INCOME/(LOSS) PER SHARE: BASIC $ (0.02) $ (0.14) $ (0.01) $ (0.31) DILUTED $ (0.02) $ (0.14) $ (0.01) $ (0.31) SHARES USED IN COMPUTING NET INCOME/(LOSS) PER SHARE: BASIC � 76,420� � 26,203� � 71,050� � 25,804� DILUTED � 76,420� � 26,203� � 71,050� � 25,804� � AKORN, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS IN THOUSANDS (UNAUDITED) � NINE MONTHS � ENDED SEPTEMBER 30 � 2006� � 2005� OPERATING ACTIVITIES Net income (loss) $ 96� $ (4,968) Adjustments to reconcile net income/(loss) to net cash provided by (used in) operating activities: Depreciation and amortization 2,444� 4,927� Amortization of deferred financing costs -� 72� Amortization of debt discounts 1,059� 876� Advances to Strides Arcolab Limited -� (1,500) Gain on Retirement of Debt -� (1,212) Non-cash stock compensation expense 1,524� 273� Changes in operating assets and liabilities: Trade accounts receivable (3,717) 4,761� Inventories (142) (330) Prepaid expenses and other current assets 218� 480� Trade accounts payable (1,007) (3,279) Product warranty 1,131� -� Accrued customer liability 403� -� Accrued expenses and other liabilities � (137) � 502� NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES 1,872� 602� INVESTING ACTIVITIES Purchases of property, plant and equipment (3,571) (744) Purchase of intangible assets � -� � (75) NET CASH USED IN INVESTING ACTIVITIES (3,571) (819) FINANCING ACTIVITIES (See Note 1 below) Repayment of long-term debt (3,009) (253) Repayment of NeoPharm Debt -� (2,500) Net borrowings under lines of credit -� -� Proceeds from common stock and warrant offerings 21,621� -� Proceeds from warrants exercised 1,213� 150� Proceeds under stock option and stock purchase plans � 606� � 734� NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 20,431� (1,869) INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 18,732� (2,086) Cash and cash equivalents at beginning of period � 791� � 4,110� CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 19,523� $ 2,024� Amount paid for interest $ 577� $ 397� Amount paid for income taxes $ 2� $ 72� � Note 1:��In March 2006, $7,298 in principal and interest related to convertible notes was retired by conversion to the common stock of Akorn, Inc. Akorn, Inc. (AMEX:AKN) today reported net sales of $14.5 million for the third quarter 2006, an increase of 32% vs. third quarter 2005 net sales of $11.0 million. Gross profit of $6.0 million or 41% of third quarter 2006 net sales, represents an increase of 62% vs. gross profit of $3.7 million or 33% of net sales for the third quarter 2005. Net loss available to common stockholders for the third quarter 2006 was $(1.2) million, or $(0.02) per diluted share vs. a $(3.6) million net loss available to common stockholders for the third quarter 2005, or $(0.14) per diluted share. During the third quarter of 2006, net loss available to common stockholders was adversely impacted by stock option expense of $0.3 million as compared to zero in the third quarter of 2005, and product development milestone expenses of $371,000 for the Akten (AK-1015) clinical trial and the Sofgen Pharmaceuticals development and supply agreement. For the nine months ended September 30, 2006 as compared to the nine months ended September 30, 2005, net sales were $56.7 million vs. $33.7 million, an increase of 68%. Gross profit was $22.6 million or 40% of net sales, vs. $11.9 million or 35% of net sales. Net loss available to common shareholders was $(0.6) million vs. a net loss of $(8.0) million. For the first nine months of 2006, net income was adversely impacted by stock option expense of $1.0 million as compared to zero in the first nine months of 2005, product development milestone expenses of $613,000, and one-time non-recurring interest expense of $1.1 million recorded upon the early retirement of convertible debt. Highlights for the Third Quarter 2006 include: -- One new business development agreement was signed, with Sofgen Pharmaceuticals, which adds one new generic drug to Akorn's product development pipeline. Combined with Fidia, Natco (2), and Cipla, this brings our total to five new business development agreements signed in 2006. -- Two new contract manufacturing supply agreements were signed, one with GeneraMedix, Inc. and one with Advanced Vision Research, Inc. As previously announced, we believe that these two supply agreements will increase Contract Manufacturing sales by approximately 50% on an annualized basis beginning in 2007. Both supply agreements are expected to contribute revenue in the fourth quarter of 2006. -- Two product approvals were received from the FDA: Bal-in-Oil injection and BSS Ophthalmic Solution, and three products were launched: Bal-in-Oil, Sufenta, and Sublimaze. To date, Akorn has received 10 ANDA product approvals in 2006. -- Clinical trials began for Akten (AK-1015), Akorn's internally developed new drug indicated for use in ocular anesthesia. Of the 200 patients that are necessary to complete the clinical trial, 104 patients have been enrolled. We expect to file the 505(b)(2) NDA in the first half of 2007. -- Eight ANDA's were submitted to the FDA. For the year, Akorn has submitted 19 ANDA's and has a total of 27 ANDA's under review with the FDA. -- A $3.5 million purchase order for the procurement of Ca-DTPA and Zn-DTPA was received from the Department of Health and Human Services (HHS). This was the first purchase order that accessed the one million unit purchase option provided for in our 2005 contract award with HHS. Akorn expects to ship this order in the fourth quarter of 2006. -- A $3.56 million equity investment was received from the Serum Institute of India, Ltd, one of Akorn's long term strategic partners. Akorn expects to use these proceeds to begin the development of its biologics product pipeline. Arthur S. Przybyl, President and Chief Executive Officer stated, "Our third quarter results continue to reflect our commitment to achieve our 2006 stated objectives: 50% year-over-year revenue increase, 40% gross margin, positive net income, 20 ANDA regulatory filings, 10 product approvals, and the completion of our lyophilization validation efforts. "Late last week, our new liquid fill injectable/lyophilization product fill line was granted clearance by the FDA to manufacture and commercialize liquid injectable products. This action will allow us to further upgrade and automate our Decatur manufacturing facility. We expect to complete validation efforts on our lyophilizers prior to year end. Commercialization of the new lyophilizers will require a successful prior approval inspection (PAI) to be conducted by the FDA. Also in the third quarter, we retired our operating lease and purchased our two lyophilizers for $1.5 million, resulting in cash savings of approximately $613,000. "We continue to develop four important products for anticipated product launches in 2008. Two proprietary products are being developed internally. AK-1015, now named Akten, is indicated for ocular anesthesia, continues to undergo clinical trials, and we expect to file our 505(b)(2) NDA in the first half of 2007. Formulation work continues on Minolok, our licensed patent from the University of Texas M.D. Anderson Cancer Center, and we expect to file a 510(k) in the first half of 2007. Two undisclosed generic products are being developed externally through Cipla and Sofgen, respectively, and we remain confident and on track for anticipated product launches in 2008. For these two products, the recent FDA announcement that specific generic drugs could be eligible for priority review is an additional benefit, potentially reducing the regulatory approval time for these two products. Akorn applauds this effort by the FDA to continue to help lower U.S. healthcare costs. "Finally, although not immediately apparent, Serum Institute of India's equity investment in Akorn is expected to be the beginning of a long term strategic partnership to expand our portfolio of products to eventually include biologics and vaccines." Conference Call Akorn will host a conference call on Monday October 30, 2006, beginning at 5:00 p.m. Eastern Time to discuss third quarter 2006 operating results. The dial-in numbers are (800) 289-0508 for domestic callers and (913) 981-5550 for international callers. Alternatively, analysts, investors and other interested parties are invited to participate by visiting the Company's website, www.akorn.com, and clicking on the live webcast icon located on the home page, or http://www.videonewswire.com/event.asp?id=35878. Please plan to log on at least ten minutes prior to the designated start time so management may begin promptly. About Akorn, Inc. Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company's website at www.akorn.com. Materials in this press release may contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements give our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual results may vary materially, and there are not guarantees about the performance of our stock. Any forward-looking statements represent our expectations or forecasts only as of the date they were made and should not be relied upon as representing our expectations or forecasts as of any subsequent date. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise, even if our expectations or forecasts change. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Other factors besides those listed there could also adversely affect our results. -0- *T AKORN, INC. CONDENSED CONSOLIDATED BALANCE SHEETS IN THOUSANDS SEPTEMBER 30, DECEMBER 31, 2006 2005 ------------- ------------- (UNAUDITED) (AUDITED) ------------- ------------- ASSETS CURRENT ASSETS Cash and cash equivalents $ 19,523 $ 791 Trade accounts receivable (less allowance for doubtful accounts of $1 and $13, respectively) 6,939 3,222 Inventories 10,421 10,279 Prepaid expenses and other current assets 1,206 1,402 ------------- ------------- TOTAL CURRENT ASSETS 38,089 15,694 PROPERTY, PLANT AND EQUIPMENT, NET 33,244 31,071 OTHER LONG-TERM ASSETS Intangibles, net 9,164 10,210 Other 98 120 ------------- ------------- TOTAL OTHER LONG-TERM ASSETS 9,262 10,330 ------------- ------------- TOTAL ASSETS $ 80,595 $ 57,095 ============= ============= LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Current installments of debt $ 387 $ 7,044 Trade accounts payable 2,039 3,046 Accrued compensation 1,674 1,519 Customer accrued liabilities 538 135 Accrued interest payable - 2,514 Accrued expenses and other liabilities 1,126 1,202 ------------- ------------- TOTAL CURRENT LIABILITIES 5,764 15,460 LONG-TERM LIABILITIES Long-term debt, less current installments 309 602 Product warranty 1,131 - ------------- ------------- TOTAL LONG-TERM LIABILITIES 1,440 602 ------------- ------------- TOTAL LIABILITIES 7,204 16,062 ------------- ------------- SHAREHOLDERS' EQUITY Common stock, no par value -- 150,000,000 shares authorized; 81,000,130 and 27,618,745 shares issued and outstanding at September 30, 2006 and December 31, 2005, respectively 136,863 67,339 Series A Preferred Stock, $1.00 par value, 257,172 shares authorized and issued, 241,122 shares outstanding at December 31, 2005 - 27,232 Series B Preferred Stock, $1.00 par value, 170,000 shares authorized, 141,000 shares issued, 74,195 outstanding at September 30, 2006 and 106,600 outstanding at December 31, 2005 7,854 10,758 Warrants to acquire common stock 7,312 13,696 Accumulated deficit (78,638) (77,992) ------------- ------------- TOTAL SHAREHOLDERS' EQUITY 73,391 41,033 ------------- ------------- TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 80,595 $ 57,095 ============= ============= *T -0- *T AKORN, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS IN THOUSANDS, EXCEPT PER SHARE DATA (UNAUDITED) THREE MONTHS ENDED NINE MONTHS ENDED SEPTEMBER 30, SEPTEMBER 30, ---------------------- ----------------------- 2006 2005 2006 2005 ----------- ---------- ----------- ----------- Revenues $ 14,490 $ 10,985 $ 56,695 $ 33,744 Cost of sales 8,539 7,317 34,056 21,881 ----------- ---------- ----------- ----------- GROSS PROFIT 5,951 3,668 22,639 11,863 Selling, general and administrative expenses 4,226 3,894 13,379 10,961 Amortization and write- down of intangibles 345 353 1,046 1,157 Research and development expenses 2,649 1,438 6,815 4,203 ----------- ---------- ----------- ----------- TOTAL OPERATING EXPENSES 7,220 5,685 21,240 16,321 ----------- ---------- ----------- ----------- OPERATING INCOME (LOSS) (1,269) (2,017) 1,399 (4,458) Interest income/(expense) - net 230 (595) (855) (1,705) Debt Retirement Gain/(Expense) - - (391) 1,212 Other Expense (28) - (57) - ------------ ---------- ---------- ----------- INCOME/(LOSS) BEFORE INCOME TAXES (1,067) (2,612) 96 (4,951) Income tax provision - 2 - 17 ----------- ---------- ----------- ----------- NET INCOME/(LOSS) (1,067) (2,614) 96 (4,968) Preferred stock dividends and adjustments (182) (1,015) (742) (2,991) ----------- ---------- ----------- ----------- NET INCOME/(LOSS) AVAILABLE TO COMMON STOCKHOLDERS $ (1,249) $ (3,629) $ (646) $ (7,959) =========== ========== =========== =========== NET INCOME/(LOSS) PER SHARE: BASIC $ (0.02) $ (0.14) $ (0.01) $ (0.31) =========== ========== =========== =========== DILUTED $ (0.02) $ (0.14) $ (0.01) $ (0.31) =========== ========== =========== =========== SHARES USED IN COMPUTING NET INCOME/(LOSS) PER SHARE: BASIC 76,420 26,203 71,050 25,804 =========== ========== =========== =========== DILUTED 76,420 26,203 71,050 25,804 =========== ========== =========== =========== *T -0- *T AKORN, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS IN THOUSANDS (UNAUDITED) NINE MONTHS ENDED SEPTEMBER 30 --------------------- 2006 2005 ---------- ---------- OPERATING ACTIVITIES Net income (loss) $ 96 $ (4,968) Adjustments to reconcile net income/(loss) to net cash provided by (used in) operating activities: Depreciation and amortization 2,444 4,927 Amortization of deferred financing costs - 72 Amortization of debt discounts 1,059 876 Advances to Strides Arcolab Limited - (1,500) Gain on Retirement of Debt - (1,212) Non-cash stock compensation expense 1,524 273 Changes in operating assets and liabilities: Trade accounts receivable (3,717) 4,761 Inventories (142) (330) Prepaid expenses and other current assets 218 480 Trade accounts payable (1,007) (3,279) Product warranty 1,131 - Accrued customer liability 403 - Accrued expenses and other liabilities (137) 502 ---------- ---------- NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES 1,872 602 INVESTING ACTIVITIES Purchases of property, plant and equipment (3,571) (744) Purchase of intangible assets - (75) ---------- ---------- NET CASH USED IN INVESTING ACTIVITIES (3,571) (819) FINANCING ACTIVITIES (See Note 1 below) Repayment of long-term debt (3,009) (253) Repayment of NeoPharm Debt - (2,500) Net borrowings under lines of credit - - Proceeds from common stock and warrant offerings 21,621 - Proceeds from warrants exercised 1,213 150 Proceeds under stock option and stock purchase plans 606 734 ---------- ---------- NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 20,431 (1,869) INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 18,732 (2,086) Cash and cash equivalents at beginning of period 791 4,110 ---------- ---------- CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 19,523 $ 2,024 ========== ========== Amount paid for interest $ 577 $ 397 Amount paid for income taxes $ 2 $ 72 Note 1: In March 2006, $7,298 in principal and interest related to convertible notes was retired by conversion to the common stock of Akorn, Inc. *T